Theseus Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Les bénéfices de Theseus Pharmaceuticals devraient diminuer de 6.3% par an. Le BPA devrait augmenter de 14.2% par an.

Informations clés

-6.3%

Taux de croissance des bénéfices

14.2%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.7%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	12 Feb 2024

Mises à jour récentes de la croissance future

Recent updates

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Feb 01

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Aug 11

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Apr 22

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:THRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-66	N/A	-55	1
12/31/2025	N/A	-53	N/A	-42	1
12/31/2024	N/A	-49	N/A	-39	1
12/31/2023	N/A	-56	N/A	-48	1
9/30/2023	N/A	-57	-50	-50	N/A
6/30/2023	N/A	-58	-46	-46	N/A
3/31/2023	N/A	-55	-44	-44	N/A
12/31/2022	N/A	-51	-33	-33	N/A
9/30/2022	N/A	-46	-33	-33	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-27	-27	-27	N/A
9/30/2021	N/A	-22	-19	-19	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-12	-5	-5	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: THRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: THRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: THRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de THRX devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: THRX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de THRX devrait être élevé dans 3 ans

Theseus Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 70% to US$6.75

Recent updates

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX).

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Key Executive exercised options to buy US$555k worth of stock.

New minor risk - Market cap size

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

New major risk - Share price stability

Price target decreased by 70% to US$6.75

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of The-630 in Patients with Gist

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Less than half of directors are independent

Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Theseus Pharmaceuticals, Inc. Appoints Steven Stein to Board of Directors

Theseus Pharmaceuticals, Inc. Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from Russell 2000 Growth Index

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Less than half of directors are independent

Theseus Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (Egfr) Inhibitors At the 2022 American Association for Cancer Research (Aacr) Annual Meeting

Theseus Pharmaceuticals Announces First Patient Treated with The-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors

Less than half of directors are independent

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance